1

**binatoprost (lash, ophthalmic)** (bio-mat-o-prost)

**Classification**
Therapeutic: hair regrowth stimulants
Pharmacologic: prostaglandins

**Pregnancy Category C**

**Indications**
Treatment of eyelash hypotrichosis.

**Action**
Increases the percent of hair in eyelashes and prolongs the duration of growth phase.

**Therapeutic Effects:**
Increases eyelash growth, improving length, thickness, and darkness.

**Pharmacokinetics**

**Absorption:** Minimal systemic absorption.
**Distribution:** Small amounts absorbed are widely distributed.
**Metabolism and Excretion:** Highly metabolized; 67% excreted in urine, 25% in feces mostly as metabolites.
**Half-life:** 45 min.

**TIME/ACTION PROFILE (improvement in eyelash growth)**

<table>
<thead>
<tr>
<th>ROUTE</th>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical</td>
<td>2 mos</td>
<td>4 mos</td>
<td>4 wk or more*</td>
</tr>
</tbody>
</table>

*Following discontinuation.

**Contraindications/Precautions**

**Contraindicated in:**
Hypersensitivity.

**Use Cautiously in:**
Active intraocular inflammation; Patients with aphakia, pseudoaphakia with a torn posterior lens capsule, or know risk factors for macular edema; OB: Use in pregnancy only if potential benefit justifies potential risk to the fetus; Lactation: Use cautiously during lactation; Pedi: Safe and effective use in children has not been established.

**Adverse Reactions/Side Effects**

**EENT:** conjunctival hyperemia, eye pruritus, hyperpigmentation of eyelids, macular edema, permanent pigmentation of the iris.

**Interactions**

Drug-Drug: May 

**Route/Dosage**

**Topical (Adults):** Apply to upper eyelid margin nightly.

**NURSING IMPLICATIONS**

**Assessment**
- Monitor intraocular pressure in patients with a history of increased intraocular pressure or who are using prostaglandin analogs for intraocular pressure reduction concurrently.

**Potential Nursing Diagnoses**
- Disturbed body image (Indications)

**Implementation**
- **Topical:** Apply once each night using the accompanying sterile applicators. Additional applications will not increase the growth of eyelashes.

**Patient/Family Teaching**
- **Topical:** Instruct patient on correct application of binatoprost. If a dose is missed, omit and apply next evening; do not double dose. Patient should wash face and remove all makeup and contact lenses prior to application. Contact lenses may be reinserted 15 min following administration. Place one drop of medication on the disposable sterile applicator and brush cautiously along the skin of the upper eyelid margin at the base of the eyelashes. Use only the applicator supplied with the product. Use each applicator for one eye then discard; reuse may result in contamination and infection. If solution gets into the eye, it is not harmful and does not need to be rinsed. Do not apply to lower lash line. Blot any excess solution outside upper eyelid margin with a tissue or other absorbent material. Do not allow tip of bottle or applicator to come in contact with surrounding structures, fingers, or any other unintended surface to avoid contamination. Instruct patient to read the Patient Information guide prior to use and with each Rx refill, in case of new information.

**Pharm/Fact**
- **Generic name:** binatoprost
- **Trade name:** Latisse
- **Pregnancy Cat:** C
- **Lactation:** Use cautiously during lactation
- **Pedi:** Safe and effective use in children has not been established
- **Availability:** Solution (binatoprost) 0.03%

**NURSING CONSIDERATIONS**

**EENT:** conjunctival hyperemia, eye pruritus, hyperpigmentation of eyelids, macular edema, permanent pigmentation of the iris.
Inform patient that eyelid skin may darken with use of bimatoprost; may be reversible with discontinuation of medication. Instillation directly into eye may result in increased brown iris pigmentation, usually permanent.

Inform patient of potential for hair growth occurring outside target treatment area if medication repeatedly touched same area of skin.

Advise patient to notify health care professional immediately if eye trauma or infection, sudden decrease in visual acuity, conjunctivitis, or eyelid reactions occur or if having ocular surgery.

Instruct patient to notify health care professional of bimatoprost use prior to intraocular pressure examinations.

Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

**Evaluation/Desired Outcomes**

- Increased length, thickness, and darkness of eyelashes. Onset is gradual and may not be noticed for 2 mos. Length, thickness, number of eyelashes, and/or direction of eyelash growth may vary between eyes. Upon discontinuation, eyelashes usually return to pretreatment level within 8 wk to 2 mos.

**Why was this drug prescribed for your patient?**